Condition: Multiple Myeloma · Sponsor: University Hospital, Toulouse
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
This description comes directly from the study's public registry record.
Hervé AVET LOISEAU, MD, PhD · +33 531 156 142 · avetloiseau.herve@iuct-oncopole.fr
Always discuss trial participation with your own doctor first.
| CHU d'Amiens | Amiens, France, France | Recruiting |
| CHU de Caen | Caen, France, France | Recruiting |
| Polyclinique du Parc Drevon | Dijon, France, France | Recruiting |
| CH Annecy Genevois | Epagny Metz- Tessy, France, France | Recruiting |
| CHU de Lille | Lille, France, France | Recruiting |
| Centre Léon Bérard | Lyon, France, France | Recruiting |
| CHU de Montpellier | Montpellier, France, France | Recruiting |
| Hôpital Saint-Louis | Paris, France, France | Recruiting |
| Hôpital Saint-Antoine | Paris, France, France | Recruiting |
| Hôpital Necker | Paris, France, France | Recruiting |
| CHU de Bordeaux | Pessac, France, France | Recruiting |
| CHU de Lyon | Pierre-Bénite, France, France | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05945524